New drug combo aims to wipe out rectal tumors before surgery
NCT ID NCT02688712
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the experimental drug galunisertib to standard chemoradiation can improve outcomes for people with locally advanced rectal cancer. About 50 participants will receive the combination over 8 weeks, followed by surgery. Researchers will also study tumor and blood samples to understand who responds and how the immune system reacts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Galunisertib (LY2157299)
What this could lead to
If successful, this could lead to a more effective treatment for locally advanced rectal cancer, potentially improving the chance of a complete tumor response before surgery.
What could go wrong
This is a small, early-phase trial (50 people) and the drug is experimental. It may not work better than standard treatment, and side effects from combining it with chemoradiation are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Providence Cancer Center
Portland, Oregon, 97213, United States